Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018).

Nocentini A, Supuran CT, Winum JY.

Expert Opin Ther Pat. 2018 Jun;28(6):493-504. doi: 10.1080/13543776.2018.1473379. Epub 2018 May 11. Review. Erratum in: Expert Opin Ther Pat. 2018 Jun;28(6):vii.

PMID:
29727210
2.

Common drug-drug interactions in antifungal treatments for superficial fungal infections.

Gupta AK, Versteeg SG, Shear NH.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):387-398. doi: 10.1080/17425255.2018.1461834. Epub 2018 Apr 26. Review.

PMID:
29633864
3.
4.

Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.

Pariser DM, Wendelken ME, Rycerz AM Jr, Gellings Lowe N, Yost JM, Lipner SR.

J Drugs Dermatol. 2018 Feb 1;17(2):168-172.

PMID:
29462224
5.
6.

In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails.

Gupta AK, Vlahovic TC, Foley KA, Lowe NG, Turner R, Brown M, Hall S.

J Dermatolog Treat. 2018 Sep;29(6):633-636. doi: 10.1080/09546634.2017.1422078. Epub 2018 Jan 10.

PMID:
29307243
7.

Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole

Pollak RA, Ilie C.

J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.

PMID:
29240863
8.

Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.

Rich P, Vlahovic TC, Joseph WS, Zane LT, Hall SB, Gellings Lowe N, Adigun CG.

Cutis. 2017 Oct;100(4):259-264.

PMID:
29136060
9.

Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.

Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T.

J Drugs Dermatol. 2017 Oct 1;16(10):1016-1021.

PMID:
29036255
10.

Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment.

Gupta AK, Versteeg SG, Shear NH.

J Cutan Med Surg. 2017 Nov/Dec;21(6):525-539. doi: 10.1177/1203475417716362. Epub 2017 Jun 22. Review.

PMID:
28639462
11.
12.

Over-the-counter and natural remedies for onychomycosis: do they really work?

Halteh P, Scher RK, Lipner SR.

Cutis. 2016 Nov;98(5):E16-E25. Review.

PMID:
28040821
13.

Topical Antifungals for Treatment of Onychomycosis.

Krasaeath R, Elizondo J.

Am Fam Physician. 2016 Nov 1;94(9):734. No abstract available.

14.
15.

Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.

Adigun CG, Vlahovic TC, McClellan MB, Thakker KD, Klein RR, Elstrom TA, Ward DB.

J Drugs Dermatol. 2016 Sep 1;15(9):1116-20.

PMID:
27602975
16.

Tinea and Onychomycosis.

Rosen T.

Semin Cutan Med Surg. 2016 Jun;35(6 Suppl):S110-3. doi: 10.12788/j.sder.2016.035.

PMID:
27537822
17.

New Antifungal Agents and New Formulations Against Dermatophytes.

Gupta AK, Foley KA, Versteeg SG.

Mycopathologia. 2017 Feb;182(1-2):127-141. doi: 10.1007/s11046-016-0045-0. Epub 2016 Aug 8. Review.

PMID:
27502503
18.

Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi.

Saunders J, Maki K, Koski R, Nybo SE.

J Pharm Pract. 2017 Dec;30(6):621-630. doi: 10.1177/0897190016660487. Epub 2016 Aug 3. Review.

PMID:
27488125
19.

Tavaborole - a treatment for onychomycosis of the toenails.

Gupta AK, Versteeg SG.

Expert Rev Clin Pharmacol. 2016 Sep;9(9):1145-52. doi: 10.1080/17512433.2016.1206467. Epub 2016 Jul 14. Review.

PMID:
27347905
20.

Response to "A financial perspective on the topical treatment of onychomycosis".

Elewski BE.

J Am Acad Dermatol. 2016 Jul;75(1):e39. doi: 10.1016/j.jaad.2016.02.1242. No abstract available.

PMID:
27317545

Supplemental Content

Loading ...
Support Center